Daily Roundup

BMT.ASX FEX.ASX DHG.ASX TLX.ASX CMP.ASX

Beamtree Secures Major Irish Contract, Fenix Fends Off Rival Bid

Beamtree Holdings Ltd has scored a significant win, securing a €2.3 million (AU$3.95 million) contract over 5 years to deliver its PICQ® software as the national data quality tool for public hospitals in the Republic of Ireland. This renewal of Beamtree's partnership with the Healthcare Pricing Office underscores the value of its market-leading data quality and clinical coding solution.

Elsewhere in the M&A space, CZR Resources Ltd has been the subject of competing takeover proposals. While CZR received a non-binding offer from Gold Valley to acquire the company for $0.31 per share, the CZR Board has unanimously recommended that shareholders accept the existing offer from Fenix Resources Ltd. The Board believes the Fenix offer remains superior, citing the conditional nature of the Gold Valley proposal and uncertainty around its funding.

CZR has also received a separate non-binding proposal from the Robe River Joint Venture to acquire CZR's Robe Mesa Iron Ore project for $75 million. The CZR Board has deemed this a potential competing proposal that could lead to a superior offer, and will engage with Robe River JV while maintaining its recommendation of the Fenix takeover.

Domain Confirms Unsolicited Approach, Telix Scores FDA Approval

In other news, Domain Holdings Australia Ltd has confirmed receiving an unsolicited, non-binding proposal from CoStar Group to acquire the company. Domain is engaged with its major shareholder, Nine Entertainment, on the proposal, though there is no certainty a transaction will eventuate.

Meanwhile, Telix Pharmaceuticals Ltd has secured a major win, with the FDA approving its new prostate cancer imaging agent Gozellix. Gozellix offers improved shelf life and distribution capabilities compared to existing products, enhancing access and efficiency for scanning clinics.

Compumedics Lands $5.7M MEG Order in China

Rounding out the day's news, Compumedics Ltd has announced a new $5.7 million order for a MEG system from Hangzhou Normal University in China. This takes Compumedics' total MEG sales orders to four, worth around $20 million in revenue. The company expects to ship and install the new system in fiscal year 2026.